Heart failure medication adjustment with limited kidney checks
Part of Heart & circulation clinical trials.
This trial tests whether it is safe and effective to increase heart failure medications (like ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT-2 inhibitors) without frequent kidney monitoring. It is for people with heart failure and reduced ejection fraction who are not yet on full doses of these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with heart failure with reduced ejection fraction (LVEF of 45% or less).
- You are currently taking at least one but not the full target dose of two specific types of heart failure medications (ACEi/ARB/ARNI, MRA, or SGLT-2i).
- Your kidney function (eGFR) is 25 or higher (measured within the last 30 days).
- Your potassium level is between 3.5 and 5.5 mmol/L.
- You do not have a known allergy or intolerance to two of the study medications, and you are not in acute heart failure crisis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether patients whose heart failure has improved can safely reduce some of their medications. If your heart function has recovered significantly and stayed stable, this trial explores whether you can gradually lower doses of heart failure drugs while staying healthy.
This study looks at whether patients with severe heart failure follow their prescribed medications as recommended by treatment guidelines. The researchers want to understand what helps or prevents patients from taking their medicines correctly, which could improve their heart function and symptoms.
This trial tests if a personalized medication plan can improve health in women hospitalized with heart failure. It aims to find the best treatment combinations for better recovery.
This trial tests whether a minimally invasive procedure called renal denervation—which reduces nerve activity in blood vessels near the kidneys—can help people with heart failure feel better and exercise with less shortness of breath. You would receive this procedure in addition to your regular heart failure medications.
This trial is testing whether people whose heart failure has improved (with better pumping strength) can safely stop taking some of their heart medications. It is for stable patients who have had significant improvement in their heart function from a low point.
This study checks how heart and kidney health are related in people with kidney disease, diabetes, high blood pressure, or high cholesterol. It is a single visit with tests to see if certain heart problems are common in these conditions.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.